MYGN Profile
Myriad Genetics, Inc., a leader in genetic testing and precision medicine, develops and commercializes a broad range of genetic tests in the United States and internationally. Founded in 1991 and headquartered in Salt Lake City, Utah, the company focuses on molecular diagnostics for oncology, women's health, and mental health applications. Myriad's portfolio includes the MyRisk Hereditary Cancer Test, which uses DNA sequencing to assess hereditary cancer risks, and the BRACAnalysis CDx Germline Companion Diagnostic Test, designed to guide therapy decisions for patients with specific metastatic cancers and BRCA variants.
In oncology, Myriad offers several key diagnostic tools such as the MyChoice CDx Companion Diagnostic Test, which evaluates homologous recombination deficiency status in ovarian cancer patients, and the Prolaris Prostate Cancer Prognostic Test, an RNA expression analysis for prostate cancer aggressiveness. The company also provides the EndoPredict Breast Cancer Prognostic Test, another RNA expression-based tool for determining breast cancer severity. Additionally, Myriad's Precise Tumor solution supports precision oncology by offering detailed tumor profiling.
Expanding beyond oncology, Myriad Genetics also addresses prenatal and mental health needs with innovative tests. The Prequel Prenatal Screen is a non-invasive test using maternal blood to detect severe chromosomal disorders in fetuses. For prospective parents, the Foresight Carrier Screen evaluates the risk of passing on recessive genetic conditions. In the mental health sphere, the GeneSight Psychotropic Test helps in selecting appropriate psychotropic medications for conditions like depression, anxiety, and ADHD by analyzing DNA genotyping.
Myriad Genetics collaborates strategically with industry leaders such as Illumina, Inc. and Intermountain Precision Genomics to enhance their offerings in germline and somatic tumor testing services. This collaboration underscores Myriad's commitment to advancing precision medicine. Through its extensive range of diagnostic tools and strategic partnerships, Myriad Genetics continues to drive innovation in genetic testing, aiming to improve patient outcomes across various medical fields.
|
